Search
Aripiprazole lauroxil
go.drugbank.com/drugs/DB14185ApprovedAripiprazole lauroxil is a long-acting injectable atypical antipsychotic drug used in the treatment of schizophrenia in adult patients. It is a prodrug of aripiprazole, which acts as a partial agonist at the D2 and 5-HT1A receptors, and ...
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A Substratesp-tert-Butylphenol-formaldehyde resin (low molecular weight)
go.drugbank.com/drugs/DB14190ApprovedSensitivity to p-tert-Butylphenol-formaldehyde resin may be identified with a clinical patch test. … p-tert-Butylphenol-formaldehyde resin is a widely used adhesive chemical used in a wide variety of commercially available products and a known dermatological sensitizer and allergen [A34290,A34291].
Synonyms: p-tert-Butylphenol-formaldehyde resin (low molecular weight)Phosphorus P-32
go.drugbank.com/drugs/DB14551InvestigationalPhosphorus P-32 is a radioactive isotope of phosphorus with beta particle-emitting radiocytotoxic activity.
Synonyms: P-32, Phosphorus P-32Hydroxyprogesterone
go.drugbank.com/drugs/DB14570InvestigationalCategories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A SubstratesEslicarbazepine
go.drugbank.com/drugs/DB14575ApprovedEslicarbazepine is an anti-epileptic medication available commercially as eslicarbazepine acetate.
Categories: Cytochrome P-450 CYP3A Inducers, Cytochrome P-450 CYP3A4 InducersFluprednidene acetate
go.drugbank.com/drugs/DB14634InvestigationalFluprednidene acetate is a corticosteroid. It has anti-inflammatory and anti-allergic properties.
Categories: Cytochrome P-450 CYP3A Inducers, Cytochrome P-450 CYP3A4 InducersCannabinol
go.drugbank.com/drugs/DB14737InvestigationalCannabinol (CBN) is a physiologically inactive constituent of Cannabis sativa.
Categories: P-glycoprotein inhibitors, Cytochrome P-450 CYP1A2 InhibitorsNarlaprevir
go.drugbank.com/drugs/DB14760InvestigationalCategories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A SubstratesAZD-1656
go.drugbank.com/drugs/DB14810InvestigationalAZD-1656 is under investigation in clinical trial NCT00747175 (A Study to Evaluate Safety, Tolerability and P-Glucose After Multiple Ascending Oral Doses of AZD1656 in Type 2 Diabetes).